<DOC>
	<DOCNO>NCT03017508</DOCNO>
	<brief_summary>The goal current proposal examine sublingual riluzole reduce anxiety people social anxiety disorder public speak task .</brief_summary>
	<brief_title>Acute Anxiolytic Effects Riluzole Subjects With Social Anxiety Disorder</brief_title>
	<detailed_description>The investigator propose conduct double-blind , placebo control crossover study examine effect BHV-0223 public speaking anxiety . Twenty participant DSM-5 define social anxiety disorder clinically significant public speaking anxiety Impromptu Speech Task enrol challenge study . Participants give BHV-0223 ( placebo ) double-blind crossover condition 1 hour prior perform 2 impromptu speech task . The two study day involve BHV-0223 ( placebo ) administration impromptu speech task separate 2 10 day allow medication washout . There final follow-up visit 2 10 day later perform complete Physical exam follow-up liver function test Complete Blood Count . Our primary outcome examine BHV-0223 's effect ( compare placebo ) self-rated anxiety impromptu speech task . The investigator also collect physiological measure anxiety , clinician-rated measure anxiety , measure speech performance secondary outcome .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Male female ( postmenopausal , surgically sterile , negative pregnancy test screening agreement utilize establish birth control , include complete abstinence , test period ) age 18 65 yr . 2 . Meet DSM5 criterion social anxiety disorder structure clinical interview ( SCID ) LSAS public speak subscale score &gt; 6 . 3 . Stable psychiatric medication . Participants must stable dos psychiatric medication month prior treatment stable dos SSRI antidepressant least 1 month prior study enrollment . As needed benzodiazepine use permit long subject refrain use benzodiazepine 48 hour prior study . 4 . Medically neurologically healthy basis physical examination , SMAC20 ( include LFT 's , TFT 's ) , VDRL , CBC w/ diff , urinalysis , urine toxicology , EKG , medical history . Individuals stable medical problem CNS effect interfere medication administer ( e.g. , oral hypoglycemics ) may include medication adjust month prior entry ; 5 . Urine toxicology screen negative drug abuse . 6 . Able provide write informed consent accord Yale Human Investigation Committee ( HIC ) guideline . 1 . Positive pregnancy test 2 . Breastfeeding female 3 . History substance abuse disorder ( ETOH , cocaine , opiates , PCP ) within last 6 month positive urine toxicology screening ( within previous 6 month ) . 4 . History pervasive developmental disorder psychotic disorder DSMIVTR criterion . 5 . Presence denture , brace , piercings time dosing , physical finding mouth tongue , opinion Principal Investigator , would likely interfere successful completion dose procedure . 6 . Participants medical condition might interfere physiological absorption motility ( ie , gastric bypass , duodenectomy ) gastric band . 7 . Participants clinically significant abnormality abnormal laboratory test result . 8 . Participant current diagnosis viral hepatitis ( HBsAG HVC ) history liver disease . 9 . Participant significant history seizure disorder single childhood febrile seizure ( eg . Epilepsy ) 10 . Participant use drug know induce inhibit CYP 1A2 metabolism ( examples inducer : rifampin , carbamazepine , etc . ; examples inhibitor : fluvoxamine , ciprofloxacin , fluoroquinolones , etc . ) within 30 day prior first study drug administration . 11 . Participants history allergic reaction riluzole relate drug . 12 . Participant history anaphylaxis , document hypersensitivity reaction , clinically important reaction drug . 13 . Participant receive another investigational drug device within 30 day ( 90 day biologics ) prior first dose currently participate investigational study involve drug administration . 14 . Participant clinically significant electrocardiogram ( ECG ) abnormality ( QTcF &gt; 450 msec ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) Screening Baseline ( Day 1 ) . 15 . Any reason , opinion Principal Investigator , would prevent participant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cross-over study</keyword>
	<keyword>Riluzole</keyword>
	<keyword>Double-blind study</keyword>
	<keyword>Speech task</keyword>
	<keyword>Social Anxiety Disorder</keyword>
</DOC>